News >

Biomarkers May Indicate Eligibility for PARP Inhibitors in Lung Cancer

Ellie Leick
Published: Monday, Aug 05, 2019

Jonathan Riess, MD, MS, an associate professor at the University of California (UC) Davis Comprehensive Cancer Center

Jonathan Riess, MD, MS

Clinical findings have indicated that presence of BRCA1/2 mutations, SLFN11, and high loss of heterozygosity (LOH) may be biomarkers for patients with lung cancer who could respond to PARP inhibitors, explained Jonathan Riess, MD, MS.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication